Catalent | CTLT - Gross Profit On Sales


Catalent reported $181M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.



Gross Profit On Sales Change Date
Agilent USD 990M 102M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Bruker USD 449.2M 69.8M Dec/2025
Centene USD 2.14B 796M Dec/2025
Charles River Laboratories USD 311.39M 6.77M Sep/2025
Cigna USD 56.45B 50.29B Sep/2025
Danaher USD 3.97B 443M Dec/2025
Dentsply International USD 441M 49M Sep/2025
Elevance Health USD 11.68B 889M Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Hologic USD 586.4M 2.9M Dec/2025
Humana USD 4.82B 754M Jun/2025
Illumina USD 759M 26M Dec/2025
Intuitive Surgical USD 1.9B 241.9M Dec/2025
IQVIA Holdings USD 1.12B 32M Dec/2025
J&J USD 16.6B 118M Dec/2025
Laboratory Of America USD 1.03B 21.1M Sep/2025
Lonza CHF 1.29B 248M Jun/2025
McKesson USD 3.68B 143M Dec/2025
Merck EUR 3.21B 186M Sep/2025
Merck USD 13.42B 431M Sep/2025
Mettler Toledo International USD 675.44M 65.98M Dec/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Quest Diagnostics USD 873M 37M Dec/2025
Repligen USD 100.52M 9.37M Sep/2025
Revvity USD 421.66M 47.06M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Supernus Pharmaceuticals USD 148.81M 21.01M Sep/2025
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
UnitedHealth USD 20.64B 77.96B Sep/2025
Waters USD 557.42M 97.44M Dec/2025
West Pharmaceutical Services USD 303.9M 9.6M Dec/2025